Pfizer's Struggles: A Rollercoaster Ride for Investors

Pfizer's revenue is being impacted by declining demand for its COVID-19 products, leading to a cut in its forecast for coronavirus product revenue this year and next. The company's shares have dropped to a 10-year low. However, it's important to consider that the decline in demand is expected as the world transitions to a post-pandemic environment. Pfizer's cost-cutting plan and recent acquisition of oncology company Seagen are also affecting earnings in the short term, but the company's long-term prospects remain positive. With an aggressive series of product launches and a reasonable valuation, now may be a good time to invest in Pfizer for the long haul.